CARVYKTI — Sales to customers (Note 9)
Products & Services · Sales to customers (Note 9)Johnson & Johnson CARVYKTI — Sales to customers (Note 9) increased by 19.4% to $1.05B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 83.5%, from $571.00M to $1.05B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ3 2025
Rolls up toTotal Revenue
How to read this metric
An increase indicates growing market demand and successful commercialization of the therapy, while a decrease may signal competitive pressure, market saturation, or supply chain constraints.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific high-value therapeutic product or spe...
Peer comparison
Comparable to product-specific revenue disclosures for oncology or specialty biologics at major pharmaceutical peers.
Metric ID:
jnj_segment_carvykti_sales_to_customers_note_9Historical Data
13 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $108.00M | $0.00 | $48.00M | $110.00M | $144.00M | $304.00M | $313.00M | $373.00M | $571.00M | $669.00M | $738.00M | $878.00M | $1.05B |
| QoQ Change | — | -100.0% | — | +129.2% | +30.9% | +111.1% | +3.0% | +19.2% | +53.1% | +17.2% | +10.3% | +19.0% | +19.4% |
| YoY Change | — | — | — | — | — | +533.3% | — | +159.0% | +87.8% | — | +135.8% | +135.4% | +83.5% |
Range$0.00 – $1.05B
CAGR+113.3%
Avg YoY Growth+189.1%
Median YoY Growth+135.6%
Current Streak10+ quarters growth
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's carvykti — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported carvykti — sales to customers (note 9) of $1.05B in Q3 2025.
- How has Johnson & Johnson's carvykti — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's carvykti — sales to customers (note 9) increased by 83.5% year-over-year, from $571.00M to $1.05B.
- What does carvykti — sales to customers (note 9) mean?
- The total revenue earned from selling a specific specialized medical product to customers.